CD4 and acute myeloid leukemia: The frequency of Tregs at the onset of immunotherapy was within or below the range in healthy subjects (3.1 ± 2.2% of CD4+ T cells; mean ± SD), which is in agreement with a recent study of AML patients in CR [49].